Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia

被引：4
|
作者：
Jamy, Omer [1 ]
Lin, Karen [2 ]
Worth, Sarah [1 ]
Bachiashvili, Kimo [1 ]
Rangaraju, Sravanti [1 ]
Vachhani, Pankit [1 ]
Bhatia, Ravi [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
[2] Grandview Med Ctr, Dept Med, Birmingham, AL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
关键词：
VENETOCLAX;
D O I：
10.1111/bjh.18229
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E35 / E37
页数：3
相关论文
共 50 条
  • [11] Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience
    Roldan Perez, Alicia
    Vazquez Paganini, Juan Andres
    Penalva Moreno, M. Jose
    Gimenez Mesa, Eugenio
    Vilches Moreno, Alba Sara
    Nunez-Torron Stock, Claudia
    Herraez Garcia, Regina
    CLINICAL CASE REPORTS, 2022, 10 (07):
  • [12] Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis
    Maiti, Abhishek
    DiNardo, Courtney D.
    Qiao, Wei
    Kadia, Tapan M.
    Jabbour, Elias J.
    Rausch, Caitlin R.
    Daver, Naval G.
    Short, Nicholas J.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Yilmaz, Musa
    Alvarado, Yesid
    Montalbano, Kathryn S.
    Wade, Allison
    Maduike, Rita E.
    Guerrero, Julio A.
    Vaughan, Kenneth
    Bivins, Carol A.
    Pierce, Sherry
    Ning, Jing
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    CANCER, 2021, 127 (22) : 4213 - 4220
  • [13] Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia
    Kugler, Eitan
    Cohen, Inbar
    Amitai, Irina
    Ram, Ron
    Frisch, Avraham
    Nachmias, Boaz
    Canaani, Jonathan
    Moshe, Yakir
    Krayem, Baher
    Aumann, Shlomzion
    Henig, Israel
    Vainstein, Vladimir
    Shargian, Liat
    Ganzel, Chezi
    Yeshurun, Moshe
    Levi, Itay
    Raanani, Pia
    Akria, Luiza
    Ofran, Yishai
    Shimony, Shai
    Wolach, Ofir
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 932 - 941
  • [14] Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia
    Aldoss, Ibrahim
    Zhang, Jianying
    Pillai, Raju
    Shouse, Geoffrey
    Sanchez, James F.
    Mei, Matthew
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (02) : E45 - E48
  • [15] Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia
    Bouligny I.M.
    Murray G.
    Doyel M.
    Patel T.
    Boron J.
    Tran V.
    Gor J.
    Hang Y.
    Alnimer Y.
    Ho T.
    Zacholski K.
    Venn C.
    Wages N.A.
    Grant S.
    Maher K.R.
    Medical Oncology, 41 (3)
  • [16] Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia
    Liang, Peiqi
    Xie, Yan
    Liu, Ziyi
    Wang, Dong
    Li, Qian
    Lu, Yin
    Xue, Shengli
    Wang, Ying
    Chen, Suning
    Wu, Deipei
    Fu, Jianhong
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1219 - 1226
  • [17] Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
    Chen, Zhangjie
    Zhen, Sisi
    Zhang, Tingting
    Shen, Yuyan
    Pang, Aiming
    Yang, Donglin
    Zhang, Rongli
    Ma, Qiaoling
    He, Yi
    Wei, Jialin
    Zhai, Weihua
    Chen, Xin
    Jiang, Erlie
    Han, Mingzhe
    Feng, Sizhou
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [18] Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
    Angotzi, Francesco
    Lessi, Federica
    Leoncin, Matteo
    Fili, Carla
    Endri, Mauro
    Lico, Albana
    Visentin, Andrea
    Pravato, Stefano
    Candoni, Anna
    Trentin, Livio
    Gurrieri, Carmela
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [19] A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
    Bang, Su-Yeon
    Park, Silvia
    Kwag, Daehun
    Lee, Jong Hyuk
    Min, Gi-June
    Park, Sung-Soo
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Lee, Jong Wook
    Kim, Hee-Je
    CANCERS, 2023, 15 (06)
  • [20] Venetoclax with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Bencini, Sara
    Peruzzi, Benedetta
    Caporale, Roberto
    Signori, Leonardo
    Fabiana, Pancani
    Maria, Vannucchi Alessandro
    Gianfaldoni, Giacomo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S289 - S289
12345